IP Library Patent Application 14596865
Patent Application
App. No. 14/596,865

PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/596,865
Abstract

Pharmaceutical compositions for intraocular administration are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as triamcinolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular administration are also described as well as pharmaceutical kits designed for administering the compositions.

Claims (39)

1 . A pharmaceutical kit, comprising:

(1) a sealed container containing an ophthalmic pharmaceutical composition comprising:

(a) a therapeutic component consisting essentially of:

(a1) a therapeutically effective quantity of an anti-bacterial agent independently selected from the group consisting of a quinolone, a fluorinated quinolone and a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof; and

(a2) a therapeutically effective quantity of an anti-inflammatory agent independently selected from the group consisting of a corticosteroid and a pharmaceutically acceptable salt, hydrate, solvate, ether, ester, acetal and ketal thereof;

(b) optionally, at least one pharmaceutically acceptable excipient suitable for intraocular administration; and

(c) optionally, a pharmaceutically acceptable carrier therefor suitable for intraocular administration;

(2) one or several drug delivery devices for administering the pharmaceutical composition; and

(3) an instruction for the use of the composition.

2 . The kit of claim 1 , wherein the drug delivery device is selected from the group consisting of devices for delivery by injection, devices for delivery via eye drops and devices for delivery via spray.

3 . The kit of claim 2 , wherein the drug delivery device is a device for delivery by injection selected from the group consisting of a needle and a cannula.

4 . The kit of claim 3 , further comprising at least one syringe to be used in conjunction with the needle and/or the cannula.

5 . The kit of claim 2 , wherein the drug delivery device is for delivery via eye drops and is selected from the group consisting of an eyedropper and a pipette.

6 . The kit of claim 1 , wherein the sealed container is:

(a) a vial containing the pharmaceutical composition; and

(b) the drug delivery device is an eyedropper detachably integrated with the vial for administering the pharmaceutical composition,

wherein the vial serves as a storage apparatus for storing the pharmaceutical composition when the eyedropper is attached to the vial, and the eyedropper is used to administer the pharmaceutical composition when the eyedropper is detached from the vial.

7 . The kit of claim 6 , further configured to allow delivery by injection, wherein the seal of the vial is penetrable by an injector and the drug delivery device is an injector selected from the group consisting of a needle and a cannula.

8 . The kit of claim 1 , wherein the sealed container is a squeezable vial comprising a tip as the drug delivery device that can be used to deliver the pharmaceutical composition when the vial is squeezed.

9 . The kit of claim 8 , wherein the squeezable vial is fabricated of a polymeric material selected from the group consisting of poly(ethyleneterephthalate), poly(vinyl chloride), poly(ethylene) and poly(propylene).

10 . The kit of claim 1 , wherein the sealed container is a threaded plastic or glass container having a needle-penetrable and/or a cannula-penetrable removable stopper screwed on the container using the thread, the kit further comprising:

(a) an eye drop dispenser as the drug delivery device;

(b) optionally, a needle or a cannula; and

(c) optionally, a syringe.

11 . The kit of claim 1 , wherein the sealed container is a squeezable vial having a removable needle-impenetrable or cannula-impenetrable heat seal attached to the opening of the vial, the kit further comprising:

(a) a snap eye drop element as the drug delivery device that is attachable to the squeezable vial and is capable of breaking the heat seal when attached to the vial for administering the pharmaceutical composition via drops;

(b) optionally, a needle or a cannula; and

(c) optionally, a syringe.

12 . The kit of claim 1 , wherein the sealed container is a squeezable vial having a needle-penetrable or cannula-penetrable seal attached to the opening of the vial, the kit further comprising:

(a) a snap eye drop element as the drug delivery device that is attachable to the squeezable viable and is capable of breaking the seal when attached to the vial for administering the pharmaceutical composition via drops;

(b) optionally, a needle or a cannula; and

(c) optionally, a syringe.

13 . The kit of claim 1 , wherein the sealed container is a syringe pre-filled with the measured quantity of the pharmaceutical composition, and the drug delivery device is a needle or a cannula for administering the pharmaceutical composition.

14 . The kit of claim 1 , wherein the anti-bacterial agent is a fluorinated quinolone.

15 . The kit of claim 14 , wherein the fluorinated quinolone is selected from the group consisting of moxifloxacin and gatifloxacin.

16 . The kit of claim 14 , wherein the fluorinated quinolone is moxifloxacin.

17 . The kit of claim 1 , wherein the corticosteroid is selected from the group consisting of triamcinolone, triamcinolone acetonide, triamcinolone diacetate, triamcinolone benetonide, triamcinolone furetonide, triamcinolone hexacetonide, betamethasone acetate, dexamethasone, fluorometholone, fluocinolone acetonide, prednisone, prednisolone, methylprednisone, corticol, cortisone, fluorocortisone, deoxycorticosterone acetate, aldosterone, budesonide and derivatives, analogs or combinations thereof.

18 . The kit of claim 17 , wherein the corticosteroid is selected from the group consisting of triamcinolone, dexamethasone, prednisone and prednisolone.

19 . The kit of claim 17 , wherein the corticosteroid is triamcinolone.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Feb 11, 2020
From: SWK FUNDING LLC
To: HARROW HEALTH, INC. (F/K/A IMPRIMIS PHARMACEUTICALS, INC.)
Reel/Frame 051786/0868 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2019
From: HARROW HEALTH, INC.
To: NOVEL DRUG SOLUTIONS LLC; EYE CARE NORTHWEST, PA
Reel/Frame 050823/0944 →
CHANGE OF NAME Recorded Jan 7, 2019
From: IMPRIMIS PHARMACEUTICALS, INC.
To: HARROW HEALTH, INC.
Reel/Frame 048019/0161 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 19, 2017
From: IMPRIMIS PHARMACEUTICALS, INC.
To: SWK FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 043258/0581 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL AT REEL/FRAME NO. 35923/0749 Recorded Jul 19, 2017
From: IMMY FUNDING LLC
To: IMPRIMIS PHARMACEUTICALS, INC.
Reel/Frame 043259/0434 →
SECURITY INTEREST Recorded Jun 16, 2015
From: IMPRIMIS PHARMACEUTICALS, INC.
To: IMMY FUNDING LLC
Reel/Frame 035923/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2015
From: FLODIN, FOREST J.; SAHAREK, JOHN P.; BAUM, MARK L.; DILZER, RICHARD
To: IMPRIMIS PHARMACEUTICALS, INC.
Reel/Frame 035161/0947 →